Allergic rhinoconjunctivitis and urticaria are found worldwide in both adults and children. As such, new non-sedating oral antihistamines represent an important breakthrough in the pharmacological treatment of allergies.
Bilastine, a new oral antihistamine, lacks both sedative side-effects and cardiotoxic effects, does not undergo hepatic metabolism, and has been shown to be effective for the symptomatic treatment of allergic rhinoconjunctivitis and urticaria.
This symposium, which cover several topics of interest presented by experts in this field, starts with a talk by Professor Tomás Chivato, which provides a general overview of the CNS safety profile of bilastine, especially the important safety aspects required for antihistamines as regards pilots and drivers, and also covers the clinical data for bilastine from planned driving and flight-simulator studies with bilastine.
